Wiśniewska R J
Department of Pharmacology, Medical Academy, Białystok, Poland.
Pol J Pharmacol. 1997 Nov-Dec;49(6):419-23.
Effects of cholecystokinin (CCK-33), caerulein (CER) and pentagastrin (PG) on arterial blood pressure and plasma renin activity (PRA) were studied in rats. The results showed that CCK-33 (106.25, 212.5 and 425.0 pmoles/kg i.v.) increased systolic and diastolic blood pressure and decreased PRA. CER used at doses: 0.37, 1.85 and 3.7 nmoles/kg (i.v.) did not change systolic blood pressure. CER administered at the higher doses slightly decreased diastolic blood pressure, evoked bradycardia and increased PRA. PG used at doses of 0.13, 1.3 and 13.0 nmoles/kg (i.v.) and the peptide given at the highest dose (13.0 nmoles/kg, i.v.) slightly increased arterial blood pressure. PG administered at all doses did not change PRA. This research shows that in spite of similarity in biochemical structure of CCK-33, CER, PG there are differences in effects of the studied peptides on arterial blood pressure and PRA. The correlation between an influence of CCK-33, CER and PG on arterial blood pressure and PRA was also observed.
研究了胆囊收缩素(CCK - 33)、蛙皮素(CER)和五肽胃泌素(PG)对大鼠动脉血压和血浆肾素活性(PRA)的影响。结果显示,CCK - 33(静脉注射剂量为106.25、212.5和425.0皮摩尔/千克)可升高收缩压和舒张压,并降低PRA。CER静脉注射剂量为0.37、1.85和3.7纳摩尔/千克时,收缩压未发生变化。较高剂量的CER可轻微降低舒张压,诱发心动过缓并增加PRA。PG静脉注射剂量为0.13、1.3和13.0纳摩尔/千克,且最高剂量(13.0纳摩尔/千克,静脉注射)的该肽可轻微升高动脉血压。所有剂量的PG均未改变PRA。该研究表明,尽管CCK - 33、CER、PG的生化结构相似,但所研究的这些肽对动脉血压和PRA的影响存在差异。同时还观察到CCK - 33、CER和PG对动脉血压和PRA影响之间的相关性。